Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis
Using 3 times the GDP per capita of China in 2023 as the threshold, the SL tablet edaravone was not cost-effective in the context of home treatment for both formulationst, but was dominance to intravenous injection in hospital treatment. The results highlighted the importance of treatment context for health economic analysis.
Authors
- Yao Yu Wu (ORCID: https://orcid.org/0000-0002-8105-0522)
- Fangxu Wang
- Shuang Sun (ORCID: https://orcid.org/0000-0002-4384-7338)
- Jie Wei (ORCID: https://orcid.org/0000-0003-3510-8241)
- Libo Tao
- Chang Liu (ORCID: https://orcid.org/0000-0003-0650-1773)
Institutions
- Peking University (CN)
Publication Details
- Journal
- Orphanet Journal of Rare Diseases
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1186/s13023-024-03381-w
- Citations
- 2
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.74